Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PARG | Q86W56 | 2/20 | 0.41 |
| ▸ | RGS4 | P49798 | 1/20 | 0.41 |
| ▸ | RGS8 | P57771 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4762278 | 0.85 | DCTPP1 (0.49) | POLBNPSR1KMT2AALDH1A1MAPT | |
| SCHEMBL4771305 | 0.84 | HTT (0.44) | POLBKMT2AMAPTMEN1SMN1; SMN2 | |
| SCHEMBL4769402 | 0.83 | POLB (0.43) | POLBSOS1KMT2ATP53ALDH1A1 | |
| SCHEMBL4765718 | 0.81 | PDE4D (0.46) | POLBNPSR1SOS1KMT2ATP53 | |
| SCHEMBL4762645 | 0.80 | PARG (0.45) | POLBNPSR1KMT2AALDH1A1MAPT | |
| SCHEMBL4762293 | 0.76 | KMT2A (0.48) | POLBSOS1KMT2AALDH1A1MEN1 | |
| SCHEMBL4767325 | 0.75 | P2RX3 (0.54) | KMT2ATP53ALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL4767319 | 0.75 | ALDH1A1 (0.42) | POLBNPSR1KMT2AALDH1A1MAPT | |
| SCHEMBL4762495 | 0.75 | MAPT (0.49) | POLBNPSR1KMT2AALDH1A1MAPT | |
| SCHEMBL4058512 | 0.74 | ADORA2A (0.38) | POLBNPSR1ALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | POLB 1001/4885NPSR1 325/4885SOS1 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.